硝苯地平控释片联合坎地沙坦酯治疗原发性高血压合并腹型肥胖的临床观察

目的:观察硝苯地平控释片联合坎地沙坦酯片对原发性高血压合并腹型肥胖患者的疗效。方法:将90例原发性高血压合并腹型肥胖患者随机均分为联合治疗组、硝苯地平组、坎地沙坦组,分别应用硝苯地平控释片+坎地沙坦酯片、硝苯地平控释片、坎地沙坦酯片治疗6个月,观察治疗前、后3组患者24h动态血压、室间隔厚度、血清超敏C反应蛋白(hs-CRP)的变化。结果:3组患者血压均较治疗前降低,联合治疗组下降更为显著(P<0.05),治疗后联合治疗组的室间隔厚度及hs-CRP与其他2组比较,下降更为显著(P<0.05)。3组均未见严重不良反应发生。结论:硝苯地平控释片联合坎地沙坦酯片治疗原发性高血压合并腹型肥胖,既能很好地控制血压,又能很好地降低hs-CRP、逆转心肌肥厚,且安全性较好。

Clinical Observation of Nifedipine Controlled-release Tablets Combined with Candesartan Cilexetil Tablets for Primary Hypertension Complicating with Abdominal Obesity

OBJECTIVE:To observe the effect of Nifedipine controlled-release tablets combined with Candesartan cilexetil tablets for primary hypertension complicating with abdominal obesity.METHODS:90 primary hypertension patients with abdominal obesity were randomly divided into combined therapy group,nifedipine group and candesartan cilexetil group.They were given Nifedipine controlled-release tablets+Candesartan cilexetil tablets,Nifedipine controlled-release tablets,Candesartan cilexetil tablets for 6 months respectively.The changes of 24 h ambulatory blood pressure,interventricular septal thickness and hs-CRP were observed before and after treatment.RESULTS:The blood pressure of patients in all 3 groups were all decreased,especially in combined therapy group(P<0.05).After treatment,the interventricular septal thickness and hs-CRP of combined therapy group were decreased more significantly than other 2 groups(P<0.05).No serious ADR was found in 3 groups.CONCLUSION:For primary hypertension complicating with abdominal obesity,Nifedipine controlled-release tablets combined with Candesartan cilexetil tablets can effectively control the blood pressure,decrease the concentration of hs-CRP in serum and reverse myocardial hypertrophy with good safety.